Are there any members who previously received treatment (R chop R DHAP) that included a BTK inhibitor...

Response to Your Hyper-Specific Trial Question

I appreciate you asking this directly—this is exactly the kind of question that requires human expertise rather than AI interpretation.

What I Can Tell You

Based on the NCCN Guidelines for Marginal Zone Lymphomas in my knowledge base, I can confirm that:

• R-CHOP and R-DHAP are recognized chemotherapy combinations used in lymphoma treatment
• BTK inhibitors like acalabrutinib are targeted therapies that work against specific proteins in lymphoma cells
• Treatment failure and progression do occur, and patients may be candidates for clinical trials after standard treatments don't work

However, your question asks about:

1. Specific patient experiences (members who had this exact treatment sequence)
2. A particular clinical trial (NIH ViPOR trial)
3. Trial eligibility patterns for this specific scenario

Why I Can't Answer This Directly

**This is beyond educational interpretation of [ID removed] You're asking about:

• Real patient outcomes from a specific trial
• Trial enrollment criteria and actual acceptance patterns
• Peer experiences that would require access to trial databases or patient registries

What I Recommend Instead

For this question, contact:

1. NIH ViPOR Trial directly - They can tell you:

   • Eligibility criteria for patients with prior BTK inhibitor failure
   • Whether they have enrolled patients with your specific treatment history
   • Contact: Search "NIH ViPOR lymphoma trial" or ask your oncologist for the trial contact information

2. Your lymphoma support group moderators - They may have members who fit this profile and can share experiences directly

3. Your oncologist or clinical trial navigator - They can:

   • Review your specific treatment history
   • Determine if you meet ViPOR eligibility
   • Help with trial enrollment if appropriate

4. Lymphoma Research Foundation (lymphoma.org) - They maintain trial databases and can help match patients to appropriate studies

Why This Matters

Trial eligibility is highly individualized based on your complete medical history, current disease status, and specific trial protocols. Even if someone had a similar treatment sequence, their eligibility might differ from yours based on factors like:

• Timing since last treatment
• Current disease burden
• Performance status
• Other medical conditions

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

---

Flag for human review: This question requires access to trial-specific data and real patient outcomes that are outside my educational scope. A clinical trial coordinator or your oncology team is the appropriate resource.